advertisement
08 November 2011

Exparel approved for post-surgery pain

Exparel (bupivacaine liposome injectable suspension) has been approved by the U.S. Food and Drug Administration to treat post-surgical pain, maker Pacira Pharmaceuticals said Monday.

0

MONDAY, Oct. 31 (HealthDay News) -- Exparel (bupivacaine liposome injectable suspension) has been approved by the U.S. Food and Drug Administration to treat post-surgical pain, maker Pacira Pharmaceuticals said Monday.

The product combines the long-acting anesthetic bupivacaine with Pacira's DepoFoam delivery technology. A single dose can provide relief for up to 72 hours and reduce the need for opioid painkillers, the drug maker said in a news release.

Exparel was evaluated in 21 clinical studies, including more than 1,300 participants. The most common side effects reported included nausea, constipation and vomiting, Pacira said.

The company is based in Parsippany, N.J.

More information

To learn more about pain, visit Medline Plus.


(Copyright © 2011 HealthDay. All rights reserved.)

This article has not necessarily been edited by Health24.

 
NEXT ON HEALTH24X
advertisement

Read Health24’s Comments Policy

Comment on this story
0 comments
Comments have been closed for this article.

Live healthier

Watch out! »

Gross fungal infections you can pick up at the gym

You go to gym to exercise. But make sure the only thing you pick up is a dumbbell and not one of these gross fungal infections.

Holiday health »

Your 10-step asthma holiday checklist

Don’t let asthma ruin your summer holiday. Whether you are travelling or embracing the summer at home, make sure you plan ahead.